Employers have the greatest potential to influence drug prices by being much more aggressive in getting PBMs and payers to have skin in the drug-pricing game.
read full article ›Not all payers make their decisions the same way. Smart payer segmentation strategies are extremely important to successful biopharmas.
read full article ›Employers have the greatest potential to influence drug prices by being much more aggressive in getting PBMs and payers to have skin in the drug-pricing game.
read full article ›As physicians lose decision-making authority to payers, drug companies need to segment markets more effectively: the patient populations prescribers are most likely to treat and that will spark the fewest access battles; and the specific payer lines-of-business least inclined to block new drugs’ use.
read full article ›Roger Longman speaks about drug pricing in the current environment, and how payers, pharma, and providers must adapt to ever-changing models of reimbursement.
read full article ›Learn why are we are seeing increasing numbers of value-based deals in the industry, how they are structured and when they make sense.
read full article ›A new, structured approach to bringing value-based reimbursement models into the mainstream is outlined, thus transforming reimbursement and fueling the shift from volume to value.
read full article ›The maturation of the biotech sector over the past few years finds fund managers focusing on a slew of clinical milestones and commercial launches in 2015, but only a handful of approvals.
read full article ›That Apple ($APPL) watch you are wearing may allow you to text and listen to music, and it can track your activity. But it may also be conducting a postmarket study that will help cut the price of some of your prescription drugs in the future.
read full article ›Gilead Sciences Inc. and AbbVie Inc. continue to vie for preferred coverage of their HCV drugs in the U.S. private payer market, and Gilead is out to an early lead when it comes to total lives covered. But much of the population is still up for grabs, and the real victor in share of lives could be determined by how the U.S. Department of Veterans Affairs and Medicaid plans respond.
read full article ›